Lucira Health, Inc. LHDX
We take great care to ensure that the data presented and summarized in this overview for Lucira Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LHDX
View allLatest Institutional Activity in LHDX
Top Purchases
Top Sells
About LHDX
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Insider Transactions at LHDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2023
|
Kevin Walter Collins Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
81,717
-25.81%
|
$0
$0.48 P/Share
|
|
Mar 07
2023
|
Richard Clavano Narido Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,382
-2.97%
|
$0
$0.45 P/Share
|
|
Mar 06
2023
|
Richard Clavano Narido Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,910
-2.32%
|
$0
$0.57 P/Share
|
|
Mar 03
2023
|
Erik T. Engelson President and Chief Executive |
SELL
Open market or private sale
|
Direct |
634,666
-79.69%
|
$634,666
$1.06 P/Share
|
|
Mar 03
2023
|
Erik T. Engelson President and Chief Executive |
BUY
Exercise of conversion of derivative security
|
Direct |
574,666
+46.62%
|
$0
$0.82 P/Share
|
|
Mar 03
2023
|
Kevin Walter Collins Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
30,102
-8.68%
|
$30,102
$1.15 P/Share
|
|
Mar 03
2023
|
Richard Clavano Narido Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,091
-8.47%
|
$25,091
$1.07 P/Share
|
|
Mar 03
2023
|
Anthony Joseph Allen Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
8,405
-5.8%
|
$8,405
$1.0 P/Share
|
|
Feb 16
2023
|
Ghazi Kashmolah Ex VP & Chief Quality Officer |
SELL
Open market or private sale
|
Direct |
5,028
-3.61%
|
$0
$0.27 P/Share
|
|
Dec 20
2022
|
Anthony Joseph Allen Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
4,263
-2.86%
|
$0
$0.16 P/Share
|
|
Dec 14
2022
|
Epiq Capital Group, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
982,417
+44.38%
|
-
|
|
Dec 14
2022
|
Epiq Capital Group, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
13,124,349
-61.98%
|
-
|
|
Dec 01
2022
|
Richard Clavano Narido Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,583
-1.45%
|
$0
$0.36 P/Share
|
|
Nov 28
2022
|
Ghazi Kashmolah Ex VP & Chief Quality Officer |
SELL
Open market or private sale
|
Direct |
7,537
-5.14%
|
$0
$0.42 P/Share
|
|
Nov 27
2022
|
Kevin Walter Collins Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
9,666
-2.71%
|
$0
$0.42 P/Share
|
|
Nov 21
2022
|
Anthony Joseph Allen Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
34,429
-9.54%
|
$0
$0.33 P/Share
|
|
Nov 17
2022
|
Ghazi Kashmolah Ex VP & Chief Quality Officer |
SELL
Open market or private sale
|
Direct |
33,247
-9.57%
|
$0
$0.38 P/Share
|
|
Nov 16
2022
|
Ghazi Kashmolah Ex VP & Chief Quality Officer |
SELL
Open market or private sale
|
Direct |
4,790
-2.59%
|
$0
$0.35 P/Share
|
|
Sep 20
2022
|
Anthony Joseph Allen Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
17,052
-8.5%
|
$17,052
$1.39 P/Share
|
|
Sep 18
2022
|
Dan George CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
343
-0.74%
|
$343
$1.38 P/Share
|